GenMark Diagnostics, Inc. (NASDAQ:GNMK) has earned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $16.25.

A number of equities research analysts have recently issued reports on the company. Canaccord Genuity restated a “buy” rating and set a $14.00 price objective (down previously from $17.00) on shares of GenMark Diagnostics in a report on Monday, August 7th. Cowen and Company restated an “outperform” rating and set a $17.00 price objective on shares of GenMark Diagnostics in a report on Wednesday, August 2nd. BidaskClub cut GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $16.00 price objective (up previously from $15.00) on shares of GenMark Diagnostics in a report on Wednesday, May 3rd.

In related news, insider Hany Massarany sold 8,311 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $9.45, for a total value of $78,538.95. Following the completion of the sale, the insider now directly owns 372,797 shares in the company, valued at $3,522,931.65. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Scott Mendel sold 2,898 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $9.45, for a total value of $27,386.10. Following the completion of the sale, the chief financial officer now owns 138,096 shares of the company’s stock, valued at $1,305,007.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,351 shares of company stock valued at $168,287. 7.50% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the stock. FMR LLC boosted its stake in shares of GenMark Diagnostics by 13.6% in the second quarter. FMR LLC now owns 8,020,502 shares of the medical equipment provider’s stock valued at $94,883,000 after buying an additional 962,822 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of GenMark Diagnostics by 15.8% in the second quarter. JPMorgan Chase & Co. now owns 4,097,767 shares of the medical equipment provider’s stock valued at $48,476,000 after buying an additional 559,629 shares during the period. Marshall Wace North America L.P. boosted its stake in shares of GenMark Diagnostics by 1,787.6% in the second quarter. Marshall Wace North America L.P. now owns 544,020 shares of the medical equipment provider’s stock valued at $6,528,000 after buying an additional 515,200 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of GenMark Diagnostics by 25.2% in the second quarter. Artisan Partners Limited Partnership now owns 2,252,831 shares of the medical equipment provider’s stock valued at $26,651,000 after buying an additional 453,329 shares during the period. Finally, Jennison Associates LLC boosted its stake in shares of GenMark Diagnostics by 14.3% in the second quarter. Jennison Associates LLC now owns 3,541,747 shares of the medical equipment provider’s stock valued at $41,899,000 after buying an additional 443,005 shares during the period.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/29/genmark-diagnostics-inc-gnmk-receives-16-25-average-price-target-from-analysts.html.

GenMark Diagnostics (NASDAQ:GNMK) traded up 0.74% during trading on Friday, hitting $9.54. The stock had a trading volume of 242,463 shares. The company has a 50 day moving average of $10.91 and a 200-day moving average of $12.05. The company’s market cap is $521.52 million. GenMark Diagnostics has a 12-month low of $8.03 and a 12-month high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.05. GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The firm had revenue of $12.36 million for the quarter, compared to the consensus estimate of $12.44 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The company’s revenue was down 1.2% on a year-over-year basis. On average, equities analysts predict that GenMark Diagnostics will post ($1.07) EPS for the current year.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Receive News & Stock Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related stocks with our FREE daily email newsletter.